Jupiter Neurosciences Inks Definitive $100M+ License for ALA-002 with $3.33M Upfront in Cash and Stock
JUNS is trading near its 52-week low of $0.155 (8.3% above the low) on elevated volume (27× avg).
Summary
Jupiter Neurosciences entered a definitive license for ALA-002, paying $3.33M upfront (cash + stock) with up to $96.67M in milestones and a 3% royalty, adding significant dilution and financial obligations to a company already under going-concern and delisting pressure.
Key Events · M&A and Partnerships · JUNS
-
Definitive License Signed
Jupiter signed a definitive Strategic Asset License Agreement with PharmAla for exclusive U.S. rights to ALA-002, a next-gen MDMA therapeutic, replacing the May 2026 non-binding term sheet.
-
Upfront Payment of $3.33M
Jupiter will pay $1.5M cash (less $600K escrow already deposited) and issue $1.83M in stock, with a VWAP reset mechanism and an equity floor price of $0.0345 to protect PharmAla against share price declines.
-
Milestone and Royalty Obligations
Up to $23.33M in development milestones (including $3.33M at Phase 3 dosing) and $73.33M in commercialization milestones, plus a 3% royalty on net sales after $2B cumulative sales.
-
Equity Dilution and Restrictions
Stock issuance capped at 19.99% of outstanding shares without shareholder approval; shares subject to 120-day lock-up and registration rights within 30 days of issuance.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences has converted its non-binding term sheet into a definitive license for PharmAla's ALA-002, a next-generation MDMA therapeutic. The agreement commits the company to $3.33 million upfront—$1.5 million in cash and $1.83 million in stock—with a VWAP reset that protects PharmAla if Jupiter's share price declines, down to a floor of $0.0345. Total milestone payments could reach $96.67 million, plus a 3% royalty after $2 billion in net sales. The equity component is capped at 19.99% of outstanding shares unless shareholders approve more, and the shares are locked up for 120 days with registration rights. For a micro-cap company already under a going-concern warning and facing Nasdaq delisting, this is a high-stakes bet: the upfront cash and stock dilution are immediate, while the milestone obligations create a long-term overhang. The deal gives Jupiter a potential pipeline asset but at a cost that strains its already fragile balance sheet.
At the time of this filing, JUNS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $0.16 to $1.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.